GE trials first angiogenesis positron emission tomography imaging agent for cancer
This article was originally published in Clinica
Executive Summary
GE Healthcare has begun cancer clinical trials for what it claims to be the first positron emission tomography (PET) imaging agent to track angiogenesis - ie the formation of new blood vessels.